5-[2-(4-Benzyl-piperidin-1-yl)-ethylsulfanyl]-1H-[1,2,4]triazol-3-ylamine

ID: ALA151901

PubChem CID: 10425979

Max Phase: Preclinical

Molecular Formula: C16H23N5S

Molecular Weight: 317.46

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Nc1n[nH]c(SCCN2CCC(Cc3ccccc3)CC2)n1

Standard InChI:  InChI=1S/C16H23N5S/c17-15-18-16(20-19-15)22-11-10-21-8-6-14(7-9-21)12-13-4-2-1-3-5-13/h1-5,14H,6-12H2,(H3,17,18,19,20)

Standard InChI Key:  QBYJJUVRVSZXBY-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 22 24  0  0  0  0  0  0  0  0999 V2000
    9.2375   -5.6792    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.7917   -5.0667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4792   -5.3417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3792   -4.3500    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.5667   -4.5167    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6250   -5.3417    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.7667   -5.7542    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   10.6125   -5.1500    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6250   -4.5167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9125   -5.7542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4792   -4.1167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2000   -4.5250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0542   -5.3417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7667   -4.5292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2000   -5.3500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9042   -4.1042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3417   -5.7542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7667   -5.3625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0542   -4.1167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0542   -5.7750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3417   -4.5375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3417   -5.3625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  1  2  0
  4  2  2  0
  5  3  1  0
  6 17  1  0
  7  3  1  0
  8  2  1  0
  9  6  1  0
 10  6  1  0
 11 12  1  0
 12 15  1  0
 13  7  1  0
 14 11  1  0
 15 10  1  0
 16  9  1  0
 17 13  1  0
 18 14  1  0
 19 14  2  0
 20 18  2  0
 21 19  1  0
 22 21  2  0
  4  5  1  0
 16 12  1  0
 22 20  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA151901

   5-[2-(4-Benzyl-piperidin-1-yl)-ethylsulfanyl]-1H-[1,2,4]triazol-3-ylamine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 317.46

Molecular Weight (Monoisotopic): 317.1674

AlogP: 2.43

#Rotatable Bonds: 6

Polar Surface Area: 70.83

Molecular Species: BASE

HBA: 5

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.52

CX Basic pKa: 8.53

CX LogP: 3.23

CX LogD: 2.06

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.80

Np Likeness Score: -1.52

References

1. Gregory TF, Wright JL, Wise LD, Meltzer LT, Serpa KA, Konkoy CS, Whittemore ER, Woodward RM..  (2000)  Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.,  10  (6): [PMID:10741546] [10.1016/s0960-894x(00)00035-4]

Source

Source(1):

• Scientific Literature